Valganciclovir thrice weekly for prophylaxis against cytomegalovirus reactivation during alemtuzumab therapy.
Hwang
Y-Y
YY
Cheung
W W W
WW
Leung
A Y H
AY
Tse
E
E
Au
W-Y
WY
Kwong
Y-L
YL
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage*; D003587:Cytomegalovirus / Q000187:drug effects*; D004341:Drug Evaluation; D015774:Ganciclovir / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D011292:Premedication; D000077562:Valganciclovir; D014775:Virus Activation / Q000187:drug effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab; D000077562:Valganciclovir; D015774:Ganciclovir